Study launched to examine hormone treatment for early pregnancy bleeding
The hormone progesterone has been shown to reduce the risk of miscarriage in women who experience bleeding early in their pregnancy.
However, progesterone is not thought to be equally effective in all women and appears to be more beneficial to those who have had several previous miscarriages.
A research team from the universities of Aberdeen and Edinburgh will now conduct a nationwide study taking place in all of Scotland's health boards.
They aim to find whether the current approach is the most appropriate and understand how progesterone treatment is implemented in practice.
The study, called PROTEA, will examine the impact on miscarriages and neonatal health.
Professor Colin Duncan of the University of Edinburgh said: 'We all want to ensure the best possible outcomes for women and babies.
'This study allows us to explore the uptake, effectiveness and impacts of progesterone supplementation in threatened miscarriage in the real world by looking outcomes from the whole of Scotland.
'The impressive record system within Scotland means we are ideally placed to carry out this important research.'
Dr Andrea Woolner is leading the study, which has been funded by the Scottish Government.
She said: 'We believe it is critical that this research is undertaken to follow up on the important findings from the clinical trials investigating this treatment to understand how progesterone may work in real-world settings.'
And she added: 'We will use routine data collected within Scottish hospitals to observe how well progesterone works in terms of preventing miscarriage when used across the population and what additional NHS resources are needed to support this service.'
Get all the latest news from around the country Follow STV News
Scan the QR code on your mobile device for all the latest news from around the country
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
25 minutes ago
- The Sun
The brain busting side-effects of Ozempic-like fat jabs revealed – ‘slashing risk of silent killers'
THEY'VE been hailed as miracle weight-loss jabs - but the effects of Ozempic-style drugs could go far beyond the waistline. New research suggests these so-called ' skinny pens ' may also supercharge your brain and protect against two killer diseases. 3 3 Scientists from Taiwan found that these fat-busting jabs may help lower the chances of developing dementia and stroke. People with type 2 diabetes and obesity who took the drugs were also less likely to die early, the researchers discovered. While everyone knows these drugs, like Wegovy and Mounjaro, help with weight and blood sugar control, experts say some of their other benefits are still a bit of a mystery. For the study, published in JAMA Network Open, experts from Chang Gung Memorial Hospita l looked at data from 60,000 people around the world. The average age was 58 and all had type 2 diabetes and obesity. About half of the group were given drugs called GLP1-RAs. These include semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) to manage their diabetes. Semaglutide is also the main ingredient in the popular diabetes drug Ozempic, which is licensed for diabetes, while Wegovy is licensed for weight loss. These drugs work by lowering appetite, slowing digestion, reducing sugar production in the liver, and helping the body make more insulin when needed. The other half of the participants were on different diabetes medications. After following everyone for seven years, the researchers found the people using GLP1-RAs had a 37 percent lower risk of dementia and were 19 percent less likely to have a stroke. Weight Loss Jabs - Pros vs Cons These conditions are often called silent killers because they can creep up without obvious symptoms until it's too late. The experts also found those on the drugs were 30 per cent less likely to die during the study period. The team saw even bigger benefits in people over 60, women, and those with a body mass index between 30 and 40. There was no difference in the chances of Parkinson's disease or brain bleeds between the groups. The academics said their findings suggest "potential neuroprotective and cerebrovascular benefits" of the drugs but they called for more studies to confirm the research. "These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity," they wrote. Commenting on the study, Professor Tara Spires-Jones, from the University of Edinburgh, said: "This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity. "This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain. "It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions. "Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity." 'This is a really exciting ' Dr Richard Oakley, from the Alzheimer's Society, said: "It is well established that diabetes and obesity can increase your risk of developing dementia. "This study supports existing evidence that shows these drugs may reduce dementia risk, particularly for people aged 60 and over who are living with type 2 diabetes and obesity. "Although interesting, we can't draw conclusions from this study alone as it is an observational study, only a small number of people who took part went on to develop dementia and as the impact of these drugs on different types of dementia is not clear. "There are clinical trials currently looking at whether drugs like these can be used to treat early-stage Alzheimer's disease, so this is a really exciting area being explored in the research fight against dementia." Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines
The Herald Scotland
30 minutes ago
- The Herald Scotland
Peggie v NHS Fife: The crucial lesson from Darlington nurses
The similarities between Sandie Peggie's changing room row against NHS Fife and eight nurses in Darlington are startling. Both centre around transgender medics' access to female-only changing rooms, with health boards in Fife and Darlington working off guidelines that allows those to use facilities of their chosen gender – rather than biological sex. And there is just a few short months separating the two rows. In summer 2023, nurses at Darlington Memorial Hospital began expressing concern at sharing changing facilities with a colleague who was born male but identifies as a woman. A legal challenge followed, with the group of nurses criticising the use of County Durham and Darlington NHS Foundation Trust's policy called 'Transitioning in the Workplace'. That allowed anyone identifying as a woman to access female changing spaces. Meanwhile, on Christmas Eve in 2023, Kirkcaldy nurse Ms Peggie complained about sharing a changing room with Dr Beth Upton, a trans woman. Her legal row with NHS Fife has become one of the biggest news stories of the year. Ms Peggie, similar to the Darlington nurses, had been told to use a cupboard or toilet cubicle to change instead of the female-only space in an attempt to resolve the issue. However, it is the differences between the cases that are the most revealing – and they could serve as an important lesson to Scotland. While Ms Peggie's employment tribunal against MHS Fife resumes on Wednesday, the Darlington nurses will not go to court until October. And yet, the Darlington Eight as they have become known have already had a win. In the wake of the Supreme Court judgment, which ruled the definition of a woman was binary and based on biological sex, UK Health Secretary Wes Streeting personally intervened on the case. He had ordered Darlington Memorial Hospital to give female nurses their own changing room. This decision by Mr Streeting is significant and has cooled what could have been a troublesome affair for the NHS in England. NHS England also declared the changing facilities at the Darlington Memorial Hospital were 'inadequate' for female staff. In Scotland it is a different story entirely. Health Secretary Neil Gray has maintained he has faith in the board at NHS Fife. He was warned in June last year the health board may have acted illegally in the female-only changing room row. Read more Unspun: In February, Mr Gray was asked by journalists if he had confidence in the management of NHS Fife, with the Health Secretary replying: 'Of course I do'. Since then, a political storm has erupted. The row over gender policy in Scotland has once again consumed Scottish politics, and it appears it is here to stay. An intervention from the Health Secretary of course would not have ended the dispute, with Ms Peggie free to continue her legal case against NHS Fife. But his intervention could have been crucial. It could have saved time, money and ended a toxic debate on both sides. The Darlington Eight showed us there was an easy solution but Scotland did not take it.
Daily Record
3 hours ago
- Daily Record
Husky 'had not eaten for a week' as cruel Scots couple banned from keeping dogs
"His owners' delay in seeking veterinary help has led to prolonged and unnecessary suffering." A cruel Scots couple have been banned from keeping dogs after starving their pet husky until the animal's ribs and spine showed through it's fur. Deborah Duncan and Reece Gordon, from Aberdeen, were convicted after their pet Kyro, a two-year-old male, grey Husky-type dog, was discovered having not had food in more than a week. He was taken into the care of the Scottish SPCA after undergoing an operation, where the extent of the neglect was discovered. Inspectors say he is now 'living the life he deserves' after being adopted. The pair appeared at Peterhead Sheriff Court on Monday, July 14, where they were found guilty. In addition to the ban, they were also ordered to carry out unpaid work in the community. Duncan had brought Kyro into the PDSA in Aberdeen after he had not eaten for over a week, and not had anything to drink for four days. He had a foreign body removed from his stomach, and was referred to the city's Vets Now Veterinary Practice for post-operative care. Upon assessment, veterinary staff were alarmed by his condition, describing him as emaciated with visible ribs, spine, and pelvic bones. Heartbreaking images showed the state he had deteriorated into as a result of not being given proper nutrition. An inspector from the Scottish SPCA said: 'We uplifted Kyro into our care due to concerns about his condition and to ensure he received appropriate aftercare. The severity of his emaciation indicated that his nutritional needs had not been met for weeks, if not longer. 'The vet had found that Kyro's condition could not be explained solely by the recent illness or the stomach obstruction, and that his lack of muscle mass suggested long-term malnutrition. Join the Daily Record WhatsApp community! "In their opinion, the dog should have weighed at least 22kg in a healthy state. Kyro, however, had clearly been deteriorating for several weeks, if not months. 'The extreme thinness of Kyro was easily identifiable by any reasonable person. It is simply unacceptable that veterinary care was not sought earlier, particularly given the owner's admission that the dog had not eaten in over a week.' Following their conviction, Duncan and Gordon were banned from keeping dogs for 36 months, ordered to carry out 96 hours of unpaid community work, and Reece Gordon was also placed under a 12-month supervision order. The Scottish SPCA inspector added: 'Kyro should have been brought to a vet a lot sooner. He was visibly underweight, weak, and had clearly been suffering. His owners' delay in seeking veterinary help has led to prolonged and unnecessary suffering. Kyro has since been adopted and now living the life he deserves.'
